According to the National Organization of Rare Diseases (NORD), a rare disease is one that affects fewer than 200,000 Americans at any given time. According to the National Institutes of Health, there are between 6,000 and 7,000 rare diseases affecting from 25 to 30 million Americans. Approximately 50% of the people affected by rare diseases are children. The NORD website has physician guides to many of these diseases aimed at primary care practitioners (http://nordphysicianguides.org/).
This educational activity will improve the clinical competence of clinicians to design, initiate, and advance antidiabetes medication treatments to achieve guideline-recommended goals at that key juncture where many of the more traditional treatments are insufficient or undesirable. Key areas of focus include clinician knowledge of the parameters of glycemic control, and in that context, the characteristics of three key therapeutic classes: the DPP-4 inhibitors, the GLP-1 receptor agonists, and the SGLT2 inhibitors. Emphasis will be placed on individualizing treatment design based on the mechanism of action of each class, its benefits, indications and contraindications, utilization in an individualized therapeutic treatment design, and medication titration to achieve goals. Also, in order to support patient achievement of individualized glycemic goals, this education aims to increase awareness of obstacles emanating from patients, as well as from providers and their care delivery systems, in order to identify steps to improve upon them.
The Evolution of Basal Insulins: One Small Step or a Giant Leap? is planned as part of a real-time virtual grand rounds series that captures the spirit of a traditional in-person live grand rounds meeting. The content of these programs will all relate to the care of some aspect of diabetes and/or one of its related conditions or comorbidities. The session will consist of faculty presentations of didactic material which will be enhanced by discussions about clinical interpretations and applications.
SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes: Methodology and Monitoring Impact is planned as part of a real-time virtual grand rounds series that captures the spirit of a traditional in-person live grand rounds meeting. The content of these programs will all relate to the care of some aspect of diabetes and/or one of its related conditions or comorbidities. The session will consist of faculty presentations of didactic material which will be enhanced by discussions about clinical interpretations and applications.
The New Insulins are Coming: What Does This Mean to the Practicing Clinician? is a virtual symposium series consisting of four (4) 60-minute sessions presented exclusively online at www.DiabetesSeriesLive.com. The live, virtual symposium series will include all of the features of a “live” clinical meeting, but will take place entirely online. The sessions will feature video-based streaming lectures, debates, panel discussions, case presentations, interactive activities such as polling and question and answer with expert presenters, and facilitated interaction with peers and other participants. Participants will be able to attend the live, virtual symposium series at their convenience, removing the limitation of time and expense of travel associated with a physical meeting. The live, virtual sessions will be recorded and hosted as an enduring educational activity certified for continuing medical education (CME) credit on DiabetesSeriesLive.com for six months after the live, virtual CME activity.
Despite the implementation of government quality-improvement programs involving payment incentives and penalties to motivate clinicians to provide guideline-driven care, substantial quality gaps in glycemic control remain. More than half of type 2 diabetes mellitus (T2DM) patients do not reach HbA1c target goals, and many patients do not maintain glycemic control. The T2DM care team is large and includes not only the patient’s primary care provider, but also endocrinologists, diabetes educators, cardiologists, ophthalmologists, nurses, and several other care professionals. However, the patient must also be considered a member of the team, as patient behavior is the most important contributor to positive outcomes. Current T2DM care too often fails to leverage the positive impact of the active involvement of the patient. The multidisciplinary experts serving as faculty for this enduring activity will attempt to enhance coordination between patients and their caregivers and provide strategies for patient engagement to improve outcomes for T2DM patients.
This course provides a comprehensive review of common pulmonary diseases including Chronic Obstructive Pulmonary Disease, Asthma, Pneumonia, Pulmonary Emboli, Pleural Effusions, Cough, Hypoxemia, Oxygen Hemoglobin Dissociation Curve, Sleep Apnea and Lung Cancer. The course also reviews the use and interpretation of pulmonary diagnostic testing and procedures including Chest X-Ray Pulmonary Function Tests, CT Scan of the Chest, and Mechanical Ventilation.
This activity will discuss important factors to consider when selecting therapy for acute migraine attacks. Patients suffering from acute migraines pose a particular challenge to primary care and family practice clinicians, as clinicians try to match patient needs with the latest treatment options. According to the NIHS, 52.8% of all visits for migraine occur in primary care settings making primary care clinicians (PCCs) among the first line of defense to address acute migraine attacks. Clinicians need to stay abreast of the latest agents, formulations, dosing, and delivery mechanisms with the goal to provide faster, easier, and more efficient administration of medications to manage patients with acute migraine headaches with fewer adverse events.
This activity will describe the 2013 ACC (American College of Cardiology)/AHA Guidelines on the Treatment of Blood Cholesterol to reduce Atherosclerotic Cardiovascular Risk in Adults for statin use. Focus will be on interpreting the control of hyperlipidemia in the context of cardiovascular risk factors.This activity will describe the 2013 ACC (American College of Cardiology)/AHA Guidelines on the Treatment of Blood Cholesterol to reduce Atherosclerotic Cardiovascular Risk in Adults for statin use. Focus will be on interpreting the control of hyperlipidemia in the context of cardiovascular risk factors.
Dr. Charles Sneiderman reviews the clinical practice guidelines for preventive services recommended for primary care providers and indicates that the guidelines of the Federal Department of Health and Human Services are the standard for reimbursable preventive care.
Dr. Charles Sneiderman reviews the responsibility of both the patient and healthcare provider in conforming to the new Electronic Medical Records (EMR) required by the Health Information Privacy and Accessibility Act (HIPAA).
Electronic medical record systems have been adopted in most primary care practices, yet many practitioners are disappointed with the EMR systems they are using. Dr. Charles Sneiderman has some insights into what happened and what you can do about it.
Hypoglycemia is common in type 1 diabetes and also common in type 2 diabetes. Hypoglycemia unawareness can occur after repeated episodes of hypoglycemia and is of great concern due to the risk of severe hypoglycemia.
Each year, the Advisory Committee on Immunization Practices (ACIP) reviews the recommended adult (anyone over 18 years old) and children 18 years and younger, immunization schedule to ensure that the schedules reflects current recommendations for the licensed vaccines.